Stay updated on Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial page
- Check5 days agoChange DetectedA sitewide NIH notice about a terminology transition appears above the page, and the site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check33 days agoChange DetectedAccess to the study record now displays a 403 Forbidden error page instead of the study content. The page header shows 403 Forbidden and includes a Home link, indicating an access restriction rather than the study details being shown.SummaryDifference18%

- Check40 days agoChange DetectedThe page's revision tag was updated to v3.7.0, replacing the previous v3.6.6 in the site's revision history.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page’s revision tag was updated from v3.6.5 to v3.6.6, indicating a site update. This update does not alter the study details or public content displayed on the page.SummaryDifference0.0%

- Check75 days agoChange DetectedThe page’s revision label was updated from v3.6.4 to v3.6.5, indicating a backend/template update. No study content or user-facing information is altered.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial page.